Table 1.
Patient and tumor characteristics.
| Arm A | Arm B | Total | (%) | |
|---|---|---|---|---|
| Number of patients | 35 | 33 | 68 | (1 0 0) |
| Sex | ||||
| Male | 21 | 17 | 38 | (56) |
| Female | 14 | 16 | 30 | (44) |
| Age at randomisation (median in years, range) | 61 (31–76) | 63 (47–80) | 62 (31–80) | |
| Karnofsky performance status | ||||
| 100 | 5 | 7 | 12 | (18) |
| 90 | 13 | 10 | 23 | (34) |
| 80 | 11 | 11 | 22 | (32) |
| 70 | 6 | 5 | 11 | (16) |
| Body mass index (median in kg/m2, range) | ||||
| Start of study | 24.8 (17.6–37.2) | 25.2 (19.1–34.1) | 25.1 (17.6–37.2) | |
| End of radiotherapy | 23.5 (15.6–37.2) | 24.1 (18.6–32.4) | 23.6 (15.6–37.2) | |
| Histology | ||||
| Ductal adenocarcinoma | 21 | 16 | 37 | (54) |
| Not performed | 14 | 17 | 31 | (46) |
| Localization of the tumor | ||||
| Pancreatic head | 20 | 21 | 41 | (60) |
| Pancreatic body | 14 | 11 | 25 | (37) |
| Pancreatic tail | 1 | 1 | 2 | (3) |
| Previous therapy | ||||
| Gemcitabine | 0 | 2 | 2 | (3) |
| None | 35 | 31 | 66 | (97) |